ArticleThe British journal of radiology2020
Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
Article in The British journal of radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 47 citations in OpenAlex.
- Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study.BMC pulmonary medicine · 2024Trial
- Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study.Journal for immunotherapy of cancer · 2023Trial
- Incidence of and risk factors for immune checkpoint inhibitor-related pneumonitis in thoracic malignancies: a prospective multicenter study.The oncologist · 2026Observational
- Immune Checkpoint Inhibitor-Related Pneumonitis in Renal Cell Carcinoma: Clinical Features, Mechanisms, and Lessons from Lung Cancer.Biomolecules · 2026Review
- Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistency.ERJ open research · 2026Article
- Serial KL-6 Changes in PD-1/PD-L1 Inhibitor-Related Pneumonitis in Non-small Cell Lung Cancer: A Single-Center Prospective Pilot Study.Tuberculosis and respiratory diseases · 2026Article
- Clinical Analysis of Relapse Risk in Immune-Checkpoint-Inhibitor-Related Pneumonitis.Journal of clinical medicine · 2026Article
- [Immune checkpoint inhibitor-related pneumonitis : Differential diagnosis strategies].Radiologie (Heidelberg, Germany) · 2026Review
- Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy.Cell death & disease · 2026Review
- Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis from COVID-19 Pneumonia Using a CT-based Radiomics Nomogram.Current medical imaging · 2025Article
- Imaging features and prognostic significance of immune checkpoint inhibitor-related pneumonitis in NSCLC.BMC cancer · 2025Article
- SevereFrontiers in oncology · 2025Article
- Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis.Journal for immunotherapy of cancer · 2024Article
- Immune checkpoint inhibitor increased mortality in lung cancer patients withFrontiers in oncology · 2024Article
- Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies - a single center study.Frontiers in oncology · 2024Article
- Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis.Journal for immunotherapy of cancer · 2023Article
- Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.Cell communication and signaling : CCS · 2023Review
- Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.International journal of molecular sciences · 2023Review
- Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.BMC cancer · 2023Article
- The radiological appearances of lung cancer treated with immunotherapy.The British journal of radiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical and radiological features of immune checkpoint inhibitor-related pneumonitis (ICI-P), a rare but serious pulmonary complication of cancer immunotherapy and to evaluate key differences between lung cancer (LC) and non-LC patients.
methods247 patients (LC,
resultsICI-P was identified in 26 patients in total (LC,
conclusionICI-P patients more often experienced other irAE prior to the development of ICI-P. The characteristics of ICI-P can differ in terms of the onset, KL-6 reliability, and chest CT findings between LC and non-LC patients. ADVANCES IN KNOWLEDGE: In ICI-P patients, a history of other irAE can be more frequently observed. Differences in disease onset and radiological patterns between LC and non-LC patients might be helpful to make a diagnosis of ICI-P; however, longitudinal observation of chest CT scans is advised to observe the pneumonitis activity irrespective of cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.